A SOLICITOR who practised for 60 years in Bournemouth, was described as 'a wonderfully eloquent advocate' and likened to ...

X-linked adrenoleukodystrophy (X-ALD) is a debilitating disease caused by mutations in the ABCD1 gene. Approximately 30% of affected boys develop the progressive ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and operational challenges.

Given the rise in newborn screening for ALD since 2019, and the untapped potential of existing genetic research, the Halls ...

A funny thing people do when you tell them a sad story is offer a consolation prize. There’s a special one for mothers mired ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

With the Zynteglo approval in the bag, eyes now turn to bluebird's second gene therapy candidate elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD), which has also been ...